(Q41445253)

30 September 2017

1 reference

title

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (English)

1 reference

30 September 2017

1 reference

J P Desager

1

1 reference

PubMed ID

9118584

30 September 2017

Y Horsmans

series ordinal

2

1 reference

30 September 2017

1 November 1996

1 reference

Clinical Pharmacokinetics

30 September 2017

1 reference

30 September 2017

31

1 reference

30 September 2017

348-371

1 reference

30 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199631050-00003

30 September 2017

0 references

cites work

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

1 reference

12 December 2020

A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1 reference

12 December 2020

Regulation of the mevalonate pathway

1 reference

12 December 2020

Management of primary hyperlipidemia

1 reference

12 December 2020

Interaction between fibre and lovastatin

1 reference

12 December 2020

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

1 reference

12 December 2020

Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

1 reference

12 December 2020

Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo

1 reference

12 December 2020

The effect of zileuton on antipyrine and indocyanine green disposition

1 reference

12 December 2020

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

1 reference

12 December 2020

Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin

1 reference

12 December 2020

Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.

1 reference

12 December 2020

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry

1 reference

12 December 2020

Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies

1 reference

12 December 2020

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

1 reference

12 December 2020

Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia

1 reference

12 December 2020

Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans

1 reference

12 December 2020

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

1 reference

12 December 2020

Effect of food on pravastatin pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

1 reference

12 December 2020

Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia

1 reference

12 December 2020

Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A

1 reference

12 December 2020

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

12 December 2020

Effects of MK-733 (simvastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on intestinal acylcoenzyme A:cholesterol acyltransferase activity in rabbits

1 reference

12 December 2020

Clinical pharmacokinetics and practical applications of simvastatin

1 reference

12 December 2020

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers

1 reference

12 December 2020

Pravastatin has no direct effect on transmembrane cationic transport systems in human erythrocytes and platelets

1 reference

12 December 2020

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1 reference

12 December 2020

Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism

1 reference

12 December 2020

Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects

1 reference

12 December 2020

Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes

1 reference

12 December 2020

Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum

1 reference

12 December 2020

Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits

1 reference

12 December 2020

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

12 December 2020

Lovastatin decreases coenzyme Q levels in humans

1 reference

12 December 2020

Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor

1 reference

12 December 2020

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

1 reference

12 December 2020

Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.

1 reference

12 December 2020

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

12 December 2020

Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.

1 reference

12 December 2020

The discovery and development of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster

1 reference

12 December 2020

Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia

1 reference

12 December 2020

Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans

1 reference

12 December 2020

Effect of lovastatin on cholesterol content of cardiac and red blood cell membranes in normal and cardiomyopathic hamsters

1 reference

12 December 2020

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

1 reference

12 December 2020

Biotransformation of fluvastatin sodium in humans

1 reference

12 December 2020

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

1 reference

12 December 2020

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1 reference

12 December 2020

Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection

1 reference

12 December 2020

The seven countries study: 2,289 deaths in 15 years

1 reference

12 December 2020

Physiological disposition of HMG-CoA-reductase inhibitors

1 reference

12 December 2020

Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum

1 reference

12 December 2020

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

1 reference

12 December 2020

Lp(a) lipoprotein: an overview

1 reference

12 December 2020

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

1 reference

12 December 2020

Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.

1 reference

12 December 2020

Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibi

1 reference

12 December 2020

High-performance liquid chromatographic method for the determination of fluvastatin in human plasma

1 reference

12 December 2020

Effects of combined bezafibrate-simvastatin appraised in healthy subjects

1 reference

12 December 2020

Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

1 reference

12 December 2020

Influence of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Pravastatin, on Corticosteroid Metabolism in Patients with Heterozygous Familial Hypercholesterolemia

1 reference

12 December 2020

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

1 reference

12 December 2020

Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol

1 reference

12 December 2020

Effects of simvastatin on apoB metabolism and LDL subfraction distribution

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

12 December 2020

Clinical implications of the biopharmaceutical properties of fluvastatin.

1 reference

12 December 2020

Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Secondary causes of hyperlipidemia.

1 reference

12 December 2020

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients

1 reference

12 December 2020

Effects of MK-733, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, on absorption and excretion of [3H]cholesterol in rabbits

1 reference

12 December 2020

Determination of pravastatin sodium and its isomeric metabolite in human urine by HPLC with UV detection

1 reference

12 December 2020

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

12 December 2020

Effects of alcohol and fluvastatin on lipid metabolism and hepatic function

1 reference

12 December 2020

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins

1 reference

12 December 2020

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

1 reference

12 December 2020

The physiological disposition of lovastatin

1 reference

12 December 2020

Plasma cholesteryl ester transfer protein

1 reference

12 December 2020

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

1 reference

12 December 2020

Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation

1 reference

12 December 2020

Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Inhibition of acyl coenzyme A: cholesterol acyltransferase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

12 December 2020

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Effect of lovastatin on cholesterol absorption in cholesterol-fed rabbits

1 reference

12 December 2020

Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction

1 reference

12 December 2020

Single-Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

1 reference

12 December 2020

Apoliproproteins and lipoproteins

1 reference

12 December 2020

Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers

1 reference

12 December 2020

Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure.

1 reference

12 December 2020

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug

1 reference

12 December 2020

Metabolic disposition of simvastatin in patients with T-tube drainage.

1 reference

12 December 2020

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

12 December 2020

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

12 December 2020

Regulation of cholesterol synthesis: mechanism for control of HMG CoA reductase

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia.

1 reference

12 December 2020

Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group

1 reference

12 December 2020

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin

1 reference

12 December 2020

New approaches to atherosclerosis: an overview

1 reference

12 December 2020

A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients

1 reference

12 December 2020

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1 reference

12 December 2020

Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects

1 reference

12 December 2020

Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia

1 reference

12 December 2020

The plasma lecithins:cholesterol acyltransferase reaction

1 reference

12 December 2020

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

1 reference

12 December 2020

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin

1 reference

12 December 2020

Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.

1 reference

12 December 2020

Acquired hyperlipidemia (secondary dyslipoproteinemias).

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man

1 reference

12 December 2020

The interaction of cholesterol absorption and cholesterol synthesis in man

1 reference

12 December 2020

Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)

1 reference

12 December 2020

Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial

1 reference

12 December 2020

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

1 reference

12 December 2020

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Pharmacology of competitive inhibitors of HMG-CoA reductase.

1 reference

12 December 2020

Effects of simvastatin, a lipoprotein-lowering drug, on the hepatic enzymes involved in drug metabolism in the Wistar rat

1 reference

12 December 2020

The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia

1 reference

12 December 2020

Molecular physiology of reverse cholesterol transport

1 reference

12 December 2020

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1 reference

12 December 2020

The interaction of fluvastatin and cyclosporin A in renal transplant patients

1 reference

12 December 2020

Gastrointestinal absorption of pravastatin in healthy subjects

1 reference

12 December 2020

Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).

1 reference

12 December 2020

Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern

1 reference

12 December 2020

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin

1 reference

12 December 2020

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

1 reference

12 December 2020

Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidaemic rabbit strain

1 reference

12 December 2020

Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase

1 reference

12 December 2020

10.2165/00003088-199631050-00003

Identifiers

DOI

1 reference

PubMed ID

9118584

Dimensions Publication ID

30 September 2017

0 references

1 reference

PubMed ID

9118584